| Ligand | Protein Symbol | Approved Name | Docking Scores |
Similarity Score |
Best Match | ||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |||||
| Canagliflozin | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -10.55 | -10.91 | -10.38 | 32.32% | CHEMBL369798 |
| Metformin | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -5.46 | -5.47 | -5.39 | 9.88% | CHEMBL366322 |
| Glimepiride | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -10.63 | -11.26 | -10.75 | 39.57% | CHEMBL332484 |
| Glipizide | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -9.78 | -10.19 | -9.95 | 44.57% | CHEMBL1632217 |
| Sitagliptin | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -9.72 | -9.88 | -10.17 | 37.61% | CHEMBL327662 |
| Canagliflozin | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -10.69 | -11.07 | N/A | 37.63% | CHEMBL328662 |
| Metformin | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -4.78 | -4.85 | N/A | 12.36% | CHEMBL582877 |
| Glimepiride | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -11.77 | -11.21 | N/A | 52.17% | CHEMBL179993 |
| Glipizide | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -10.69 | -10.48 | N/A | 45.75% | CHEMBL179993 |
| Sitagliptin | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -10.20 | -9.85 | N/A | 43.54% | CHEMBL1957808 |
| Canagliflozin | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -10.36 | -10.91 | -10.35 | 37.04% | CHEMBL502620 |
| Metformin | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -5.34 | -5.07 | -5.07 | 12.36% | CHEMBL582877 |
| Glimepiride | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -10.44 | -11.44 | -10.41 | 43.84% | CHEMBL455039 |
| Glipizide | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -9.56 | -10.03 | -9.59 | 44.57% | CHEMBL1632217 |
| Sitagliptin | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -10.32 | -9.40 | -10.57 | 36.45% | CHEMBL2059590 |
| Canagliflozin | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -10.33 | -10.80 | N/A | 38.92% | CHEMBL549 |
| Metformin | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -5.10 | -4.95 | N/A | 12.36% | CHEMBL582877 |
| Glimepiride | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -10.80 | -11.69 | N/A | 44.53% | CHEMBL1933402 |
| Glipizide | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -9.63 | -10.35 | N/A | 44.79% | CHEMBL388247 |
| Sitagliptin | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -9.25 | -10.03 | N/A | 43.54% | CHEMBL1957808 |
| Canagliflozin | AA1R_HUMAN | adenosine A1 receptor | -10.16 | -10.08 | -7.25 | 35.71% | CHEMBL2260640 |
| Metformin | AA1R_HUMAN | adenosine A1 receptor | -4.63 | -4.32 | -5.19 | 6.48% | CHEMBL329774 |
| Glimepiride | AA1R_HUMAN | adenosine A1 receptor | -9.95 | -9.57 | -9.21 | 32.00% | CHEMBL211521 |
| Glipizide | AA1R_HUMAN | adenosine A1 receptor | -9.55 | -9.37 | -9.36 | 39.50% | CHEMBL3765424 |
| Sitagliptin | AA1R_HUMAN | adenosine A1 receptor | -8.69 | -8.87 | -7.67 | 32.10% | CHEMBL3355971 |
| Canagliflozin | AA2AR_HUMAN | adenosine A2a receptor | -10.07 | -10.29 | -10.33 | 34.07% | CHEMBL4078771 |
| Metformin | AA2AR_HUMAN | adenosine A2a receptor | -4.84 | -5.03 | -5.13 | 8.91% | CHEMBL1099100 |
| Glimepiride | AA2AR_HUMAN | adenosine A2a receptor | -9.34 | -10.16 | -9.44 | 33.01% | CHEMBL488541 |
| Glipizide | AA2AR_HUMAN | adenosine A2a receptor | -9.39 | -9.68 | -9.61 | 40.00% | CHEMBL488541 |
| Sitagliptin | AA2AR_HUMAN | adenosine A2a receptor | -8.96 | -9.35 | -9.75 | 31.92% | CHEMBL392168 |
| Canagliflozin | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -11.20 | -10.24 | -10.34 | 32.51% | CHEMBL315515 |
| Metformin | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -5.86 | -5.55 | -5.68 | 18.52% | CHEMBL1956097 |
| Glimepiride | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -11.92 | -10.99 | -10.18 | 48.84% | CHEMBL575621 |
| Glipizide | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -11.44 | -10.10 | -8.87 | 42.36% | CHEMBL575621 |
| Sitagliptin | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -10.74 | -10.39 | -11.02 | 33.69% | CHEMBL74832 |
| Canagliflozin | ACE_HUMAN | angiotensin I converting enzyme | -9.78 | -9.60 | -7.34 | 27.08% | CHEMBL284898 |
| Metformin | ACE_HUMAN | angiotensin I converting enzyme | -5.50 | -5.79 | -5.21 | 5.49% | CHEMBL101360 |
| Glimepiride | ACE_HUMAN | angiotensin I converting enzyme | -11.21 | -10.23 | -7.95 | 38.46% | CHEMBL136312 |
| Glipizide | ACE_HUMAN | angiotensin I converting enzyme | -9.92 | -9.19 | -8.01 | 36.59% | CHEMBL148616 |
| Sitagliptin | ACE_HUMAN | angiotensin I converting enzyme | -9.63 | -9.66 | -8.74 | 48.33% | CHEMBL4086264 |
| Canagliflozin | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -7.82 | N/A | N/A | 16.02% | CHEMBL386114 |
| Metformin | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -4.61 | N/A | N/A | 3.66% | CHEMBL386114 |
| Glimepiride | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -8.26 | N/A | N/A | 25.45% | CHEMBL386114 |
| Glipizide | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -7.68 | N/A | N/A | 27.88% | CHEMBL386114 |
| Sitagliptin | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -7.15 | N/A | N/A | 27.50% | CHEMBL386114 |
| Canagliflozin | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -6.78 | -8.18 | -5.74 | N/A | N/A |
| Metformin | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -5.16 | -5.79 | -5.14 | N/A | N/A |
| Glimepiride | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -6.16 | -6.99 | -6.57 | N/A | N/A |
| Glipizide | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -9.07 | -9.35 | -7.32 | N/A | N/A |
| Sitagliptin | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -7.52 | -8.30 | -6.68 | N/A | N/A |
| Canagliflozin | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -8.66 | -0.25 | N/A | 41.24% | CHEMBL554725 |
| Metformin | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -5.24 | -5.02 | N/A | 15.91% | CHEMBL477542 |
| Glimepiride | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -10.56 | 5.66 | N/A | 52.17% | CHEMBL179993 |
| Glipizide | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -10.14 | -3.93 | N/A | 45.75% | CHEMBL179993 |
| Sitagliptin | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -9.50 | -4.70 | N/A | 38.27% | CHEMBL343659 |
| Canagliflozin | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -8.66 | -7.48 | N/A | 40.10% | CHEMBL3545181 |
| Metformin | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -5.29 | -5.19 | N/A | 15.91% | CHEMBL477542 |
| Glimepiride | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -10.75 | -9.67 | N/A | 37.66% | CHEMBL71531 |
| Glipizide | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -9.52 | -9.33 | N/A | 34.92% | CHEMBL4075391 |
| Sitagliptin | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -9.64 | -7.77 | N/A | 35.48% | CHEMBL438822 |
| Canagliflozin | ADRB2_HUMAN | adrenoceptor beta 2 | -10.18 | -9.94 | -10.56 | 34.82% | CHEMBL1683942 |
| Metformin | ADRB2_HUMAN | adrenoceptor beta 2 | -5.38 | -5.44 | -5.23 | 7.03% | CHEMBL332010 |
| Glimepiride | ADRB2_HUMAN | adrenoceptor beta 2 | -10.57 | -10.84 | -11.60 | 44.77% | CHEMBL57430 |
| Glipizide | ADRB2_HUMAN | adrenoceptor beta 2 | -9.49 | -10.08 | -10.51 | 46.28% | CHEMBL323113 |
| Sitagliptin | ADRB2_HUMAN | adrenoceptor beta 2 | -10.33 | -10.96 | -10.64 | 33.99% | CHEMBL1814273 |
| Canagliflozin | AGTR2_HUMAN | angiotensin II receptor type 2 | -10.27 | -9.96 | -9.86 | 29.95% | CHEMBL216746 |
| Metformin | AGTR2_HUMAN | angiotensin II receptor type 2 | -4.59 | -4.88 | -4.66 | 5.93% | CHEMBL3350599 |
| Glimepiride | AGTR2_HUMAN | angiotensin II receptor type 2 | -10.06 | -10.30 | -10.24 | 37.22% | CHEMBL214525 |
| Glipizide | AGTR2_HUMAN | angiotensin II receptor type 2 | -9.22 | -10.02 | -8.65 | 44.30% | CHEMBL304620 |
| Sitagliptin | AGTR2_HUMAN | angiotensin II receptor type 2 | -9.90 | -9.59 | -9.78 | 35.00% | CHEMBL3144487 |
| Canagliflozin | ALDR_HUMAN | aldo-keto reductase family 1 member B | -9.78 | -10.44 | -10.67 | 27.81% | CHEMBL71562 |
| Metformin | ALDR_HUMAN | aldo-keto reductase family 1 member B | -6.09 | -6.61 | -6.03 | 5.47% | CHEMBL293869 |
| Glimepiride | ALDR_HUMAN | aldo-keto reductase family 1 member B | -10.83 | -10.26 | -11.60 | 41.86% | CHEMBL19744 |
| Glipizide | ALDR_HUMAN | aldo-keto reductase family 1 member B | -10.20 | -10.79 | -11.03 | 38.92% | CHEMBL19744 |
| Sitagliptin | ALDR_HUMAN | aldo-keto reductase family 1 member B | -10.58 | -10.20 | -10.19 | 36.24% | CHEMBL84446 |
| Canagliflozin | AMPN_HUMAN | alanyl aminopeptidase, membrane | -9.93 | -9.38 | -10.13 | 27.37% | CHEMBL1821980 |
| Metformin | AMPN_HUMAN | alanyl aminopeptidase, membrane | -5.82 | -5.91 | -6.03 | 7.21% | CHEMBL2022238 |
| Glimepiride | AMPN_HUMAN | alanyl aminopeptidase, membrane | -9.94 | -9.88 | -10.86 | 33.14% | CHEMBL2022238 |
| Glipizide | AMPN_HUMAN | alanyl aminopeptidase, membrane | -9.78 | -9.40 | -9.91 | 36.16% | CHEMBL1077585 |
| Sitagliptin | AMPN_HUMAN | alanyl aminopeptidase, membrane | -9.31 | -9.90 | -9.00 | 36.36% | CHEMBL1941150 |
| Canagliflozin | AOFA_HUMAN | monoamine oxidase A | -11.13 | -11.47 | -10.01 | 27.68% | CHEMBL3288293 |
| Metformin | AOFA_HUMAN | monoamine oxidase A | -5.30 | -5.20 | -5.57 | 7.14% | CHEMBL1796459 |
| Glimepiride | AOFA_HUMAN | monoamine oxidase A | -12.11 | -12.29 | -10.47 | 29.29% | CHEMBL3415788 |
| Glipizide | AOFA_HUMAN | monoamine oxidase A | -11.05 | -10.99 | -10.60 | 34.81% | CHEMBL3605368 |
| Sitagliptin | AOFA_HUMAN | monoamine oxidase A | -10.63 | -10.39 | -11.15 | 30.77% | CHEMBL3415789 |
| Canagliflozin | AOFB_HUMAN | monoamine oxidase B | -10.79 | -11.02 | -10.94 | 28.42% | CHEMBL600391 |
| Metformin | AOFB_HUMAN | monoamine oxidase B | -5.21 | -5.21 | -5.15 | 10.53% | CHEMBL903 |
| Glimepiride | AOFB_HUMAN | monoamine oxidase B | -11.78 | -11.82 | -11.54 | 33.33% | CHEMBL3604126 |
| Glipizide | AOFB_HUMAN | monoamine oxidase B | -10.41 | -10.55 | -10.70 | 35.00% | CHEMBL3605366 |
| Sitagliptin | AOFB_HUMAN | monoamine oxidase B | -10.52 | -10.73 | -10.84 | 30.77% | CHEMBL3415789 |
| Canagliflozin | BACE1_HUMAN | beta-secretase 1 | -8.74 | -8.63 | -9.96 | 37.00% | CHEMBL1209054 |
| Metformin | BACE1_HUMAN | beta-secretase 1 | -4.98 | -4.59 | -4.92 | 14.55% | CHEMBL583178 |
| Glimepiride | BACE1_HUMAN | beta-secretase 1 | -7.78 | -9.07 | -9.05 | 40.85% | CHEMBL3354254 |
| Glipizide | BACE1_HUMAN | beta-secretase 1 | -8.40 | -8.23 | -9.08 | 43.95% | CHEMBL409875 |
| Sitagliptin | BACE1_HUMAN | beta-secretase 1 | -8.08 | -8.35 | -8.92 | 44.78% | CHEMBL1258003 |
| Canagliflozin | CAH2_HUMAN | carbonic anhydrase 2 | -9.17 | -8.92 | -8.22 | 30.12% | CHEMBL3763841 |
| Metformin | CAH2_HUMAN | carbonic anhydrase 2 | -5.86 | -5.83 | -5.67 | 18.06% | CHEMBL4080055 |
| Glimepiride | CAH2_HUMAN | carbonic anhydrase 2 | -8.74 | -8.54 | -8.59 | 63.87% | CHEMBL3354131 |
| Glipizide | CAH2_HUMAN | carbonic anhydrase 2 | -8.43 | -7.92 | -7.89 | 72.54% | CHEMBL4083255 |
| Sitagliptin | CAH2_HUMAN | carbonic anhydrase 2 | -9.19 | -8.81 | -8.77 | 34.60% | CHEMBL306510 |
| Canagliflozin | CASP1_HUMAN | caspase 1 | -7.54 | -8.45 | -7.20 | 27.89% | CHEMBL1222833 |
| Metformin | CASP1_HUMAN | caspase 1 | -4.73 | -5.36 | -5.26 | 6.35% | CHEMBL196571 |
| Glimepiride | CASP1_HUMAN | caspase 1 | -8.59 | -8.42 | -8.23 | 33.33% | CHEMBL1221597 |
| Glipizide | CASP1_HUMAN | caspase 1 | -7.89 | -7.79 | -7.56 | 37.87% | CHEMBL381667 |
| Sitagliptin | CASP1_HUMAN | caspase 1 | -7.40 | -8.05 | -7.39 | 33.70% | CHEMBL58012 |
| Canagliflozin | CDK5_HUMAN | cyclin dependent kinase 5 | -8.75 | -9.48 | -8.95 | 27.54% | CHEMBL1985206 |
| Metformin | CDK5_HUMAN | cyclin dependent kinase 5 | -4.68 | -4.72 | -5.42 | 7.14% | CHEMBL1992371 |
| Glimepiride | CDK5_HUMAN | cyclin dependent kinase 5 | -8.81 | -9.85 | -9.52 | 33.99% | CHEMBL1964937 |
| Glipizide | CDK5_HUMAN | cyclin dependent kinase 5 | -8.23 | -8.46 | -9.48 | 35.79% | CHEMBL2005528 |
| Sitagliptin | CDK5_HUMAN | cyclin dependent kinase 5 | -8.62 | -9.29 | -9.86 | 30.74% | CHEMBL1981047 |
| Canagliflozin | CHLE_HUMAN | butyrylcholinesterase | -10.15 | -10.12 | -10.28 | 33.88% | CHEMBL523005 |
| Metformin | CHLE_HUMAN | butyrylcholinesterase | -5.21 | -5.19 | -5.67 | 18.52% | CHEMBL1956097 |
| Glimepiride | CHLE_HUMAN | butyrylcholinesterase | -10.65 | -10.44 | -10.23 | 34.44% | CHEMBL3918754 |
| Glipizide | CHLE_HUMAN | butyrylcholinesterase | -10.57 | -10.53 | -10.52 | 39.66% | CHEMBL3628054 |
| Sitagliptin | CHLE_HUMAN | butyrylcholinesterase | -9.78 | -9.85 | -10.25 | 36.63% | CHEMBL4089230 |
| Canagliflozin | CNR1_HUMAN | cannabinoid receptor 1 | -8.76 | -10.13 | -11.59 | 37.34% | CHEMBL3923170 |
| Metformin | CNR1_HUMAN | cannabinoid receptor 1 | -5.34 | -5.39 | -5.84 | 7.84% | CHEMBL515604 |
| Glimepiride | CNR1_HUMAN | cannabinoid receptor 1 | -10.23 | -11.80 | -10.65 | 44.72% | CHEMBL523603 |
| Glipizide | CNR1_HUMAN | cannabinoid receptor 1 | -9.20 | -9.56 | -11.49 | 52.41% | CHEMBL375960 |
| Sitagliptin | CNR1_HUMAN | cannabinoid receptor 1 | -8.92 | -10.12 | -10.44 | 37.98% | CHEMBL4083220 |
| Canagliflozin | CNR2_HUMAN | cannabinoid receptor 2 | -11.69 | -10.87 | N/A | 37.34% | CHEMBL3923170 |
| Metformin | CNR2_HUMAN | cannabinoid receptor 2 | -5.05 | -5.49 | N/A | 9.43% | CHEMBL1422818 |
| Glimepiride | CNR2_HUMAN | cannabinoid receptor 2 | -10.92 | -11.86 | N/A | 43.56% | CHEMBL404539 |
| Glipizide | CNR2_HUMAN | cannabinoid receptor 2 | -11.45 | -10.72 | N/A | 46.52% | CHEMBL3955332 |
| Sitagliptin | CNR2_HUMAN | cannabinoid receptor 2 | -10.38 | -10.28 | N/A | 45.35% | CHEMBL1765269 |
| Canagliflozin | COLI_HUMAN | proopiomelanocortin | -9.91 | -10.14 | -8.75 | N/A | N/A |
| Metformin | COLI_HUMAN | proopiomelanocortin | -5.04 | -5.05 | -4.71 | N/A | N/A |
| Glimepiride | COLI_HUMAN | proopiomelanocortin | -11.09 | -10.71 | -9.66 | N/A | N/A |
| Glipizide | COLI_HUMAN | proopiomelanocortin | -10.13 | -9.87 | -9.40 | N/A | N/A |
| Sitagliptin | COLI_HUMAN | proopiomelanocortin | -9.42 | -9.45 | -9.47 | N/A | N/A |
| Canagliflozin | COMT_HUMAN | catechol-O-methyltransferase | -7.30 | -7.49 | -8.03 | 25.10% | CHEMBL1089630 |
| Metformin | COMT_HUMAN | catechol-O-methyltransferase | -4.78 | -4.49 | -5.88 | 4.17% | CHEMBL1089537 |
| Glimepiride | COMT_HUMAN | catechol-O-methyltransferase | -7.09 | -7.17 | -6.89 | 24.14% | CHEMBL3819488 |
| Glipizide | COMT_HUMAN | catechol-O-methyltransferase | -7.08 | -7.24 | -6.70 | 22.99% | CHEMBL3819488 |
| Sitagliptin | COMT_HUMAN | catechol-O-methyltransferase | -6.86 | -6.75 | -7.11 | 26.88% | CHEMBL3819488 |
| Canagliflozin | CRP_HUMAN | C-reactive protein | -6.82 | -6.70 | N/A | N/A | N/A |
| Metformin | CRP_HUMAN | C-reactive protein | -4.33 | -4.83 | N/A | N/A | N/A |
| Glimepiride | CRP_HUMAN | C-reactive protein | -7.17 | -6.40 | N/A | N/A | N/A |
| Glipizide | CRP_HUMAN | C-reactive protein | -6.74 | -7.01 | N/A | N/A | N/A |
| Sitagliptin | CRP_HUMAN | C-reactive protein | -6.98 | -6.57 | N/A | N/A | N/A |
| Canagliflozin | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | 0.47 | N/A | N/A | 25.30% | CHEMBL464012 |
| Metformin | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -6.02 | N/A | N/A | 7.58% | CHEMBL184637 |
| Glimepiride | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | 1.20 | N/A | N/A | 33.49% | CHEMBL387136 |
| Glipizide | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | 1.21 | N/A | N/A | 32.18% | CHEMBL3609013 |
| Sitagliptin | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -6.29 | N/A | N/A | 28.33% | CHEMBL402076 |
| Canagliflozin | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -9.46 | -8.24 | -8.85 | 24.68% | CHEMBL1644085 |
| Metformin | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -5.15 | -5.29 | -5.18 | 12.31% | CHEMBL2347630 |
| Glimepiride | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -11.34 | -9.07 | -9.06 | 40.88% | CHEMBL2029611 |
| Glipizide | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -9.66 | -8.06 | -7.96 | 41.29% | CHEMBL568245 |
| Sitagliptin | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -9.79 | -7.67 | -8.66 | 36.22% | CHEMBL1949884 |
| Canagliflozin | DRD2_HUMAN | dopamine receptor D2 | -10.10 | N/A | N/A | 37.44% | CHEMBL597900 |
| Metformin | DRD2_HUMAN | dopamine receptor D2 | -5.14 | N/A | N/A | 13.24% | CHEMBL132575 |
| Glimepiride | DRD2_HUMAN | dopamine receptor D2 | -10.59 | N/A | N/A | 47.97% | CHEMBL1224698 |
| Glipizide | DRD2_HUMAN | dopamine receptor D2 | -9.83 | N/A | N/A | 44.79% | CHEMBL388247 |
| Sitagliptin | DRD2_HUMAN | dopamine receptor D2 | -9.97 | N/A | N/A | 42.77% | CHEMBL122165 |
| Canagliflozin | DRD3_HUMAN | dopamine receptor D3 | -9.48 | N/A | N/A | 37.44% | CHEMBL102414 |
| Metformin | DRD3_HUMAN | dopamine receptor D3 | -4.97 | N/A | N/A | 7.59% | CHEMBL552366 |
| Glimepiride | DRD3_HUMAN | dopamine receptor D3 | -10.44 | N/A | N/A | 47.97% | CHEMBL1224698 |
| Glipizide | DRD3_HUMAN | dopamine receptor D3 | -9.85 | N/A | N/A | 44.79% | CHEMBL388247 |
| Sitagliptin | DRD3_HUMAN | dopamine receptor D3 | -9.62 | N/A | N/A | 37.85% | CHEMBL113956 |
| Canagliflozin | DRD4_HUMAN | dopamine receptor D4 | -10.83 | -10.74 | N/A | 36.81% | CHEMBL2308105 |
| Metformin | DRD4_HUMAN | dopamine receptor D4 | -5.13 | -4.99 | N/A | 7.89% | CHEMBL327310 |
| Glimepiride | DRD4_HUMAN | dopamine receptor D4 | -11.40 | -11.53 | N/A | 35.10% | CHEMBL3590080 |
| Glipizide | DRD4_HUMAN | dopamine receptor D4 | -9.91 | -10.00 | N/A | 37.70% | CHEMBL106917 |
| Sitagliptin | DRD4_HUMAN | dopamine receptor D4 | -9.99 | -10.25 | N/A | 37.58% | CHEMBL117537 |
| Canagliflozin | EDN1_HUMAN | endothelin 1 | -8.60 | N/A | N/A | N/A | N/A |
| Metformin | EDN1_HUMAN | endothelin 1 | -4.68 | N/A | N/A | N/A | N/A |
| Glimepiride | EDN1_HUMAN | endothelin 1 | -9.47 | N/A | N/A | N/A | N/A |
| Glipizide | EDN1_HUMAN | endothelin 1 | -8.85 | N/A | N/A | N/A | N/A |
| Sitagliptin | EDN1_HUMAN | endothelin 1 | -9.59 | N/A | N/A | N/A | N/A |
| Canagliflozin | ESR1_HUMAN | estrogen receptor 1 | -9.52 | -8.36 | -8.38 | 39.04% | CHEMBL3764690 |
| Metformin | ESR1_HUMAN | estrogen receptor 1 | -5.15 | -5.16 | -5.26 | 10.94% | CHEMBL3597502 |
| Glimepiride | ESR1_HUMAN | estrogen receptor 1 | -9.46 | -9.15 | -8.94 | 37.89% | CHEMBL243571 |
| Glipizide | ESR1_HUMAN | estrogen receptor 1 | -8.87 | -8.53 | -8.66 | 36.36% | CHEMBL4075710 |
| Sitagliptin | ESR1_HUMAN | estrogen receptor 1 | -8.78 | -9.17 | -9.64 | 34.66% | CHEMBL153115 |
| Canagliflozin | FABP5_HUMAN | fatty acid binding protein 5 | -9.11 | -6.71 | -6.61 | 21.01% | CHEMBL248120 |
| Metformin | FABP5_HUMAN | fatty acid binding protein 5 | -4.83 | -4.34 | -4.29 | 3.97% | CHEMBL3959018 |
| Glimepiride | FABP5_HUMAN | fatty acid binding protein 5 | -10.18 | -7.03 | -7.30 | 22.14% | CHEMBL3957282 |
| Glipizide | FABP5_HUMAN | fatty acid binding protein 5 | -9.65 | -6.68 | -7.12 | 24.06% | CHEMBL3941588 |
| Sitagliptin | FABP5_HUMAN | fatty acid binding protein 5 | -9.08 | -6.78 | -6.93 | 22.27% | CHEMBL3941588 |
| Canagliflozin | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -9.70 | N/A | N/A | 29.17% | CHEMBL305660 |
| Metformin | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -5.42 | N/A | N/A | 6.37% | CHEMBL67237 |
| Glimepiride | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -10.26 | N/A | N/A | 35.66% | CHEMBL588119 |
| Glipizide | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -9.40 | N/A | N/A | 34.33% | CHEMBL1973363 |
| Sitagliptin | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -8.56 | N/A | N/A | 30.74% | CHEMBL1981047 |
| Canagliflozin | GLRA3_HUMAN | glycine receptor alpha 3 | -10.71 | -9.44 | -9.92 | 13.40% | CHEMBL4070615 |
| Canagliflozin | GLRA3_HUMAN | glycine receptor alpha 3 | -10.18 | N/A | N/A | 13.40% | CHEMBL4070615 |
| Metformin | GLRA3_HUMAN | glycine receptor alpha 3 | -5.23 | -5.16 | -5.38 | 2.53% | CHEMBL4070615 |
| Metformin | GLRA3_HUMAN | glycine receptor alpha 3 | -5.30 | N/A | N/A | 2.53% | CHEMBL4070615 |
| Glimepiride | GLRA3_HUMAN | glycine receptor alpha 3 | -10.30 | -10.65 | -10.93 | 27.51% | CHEMBL4074873 |
| Glimepiride | GLRA3_HUMAN | glycine receptor alpha 3 | -10.56 | N/A | N/A | 27.51% | CHEMBL4074873 |
| Glipizide | GLRA3_HUMAN | glycine receptor alpha 3 | -8.98 | -9.29 | -9.38 | 32.61% | CHEMBL4074873 |
| Glipizide | GLRA3_HUMAN | glycine receptor alpha 3 | -9.38 | N/A | N/A | 32.61% | CHEMBL4074873 |
| Sitagliptin | GLRA3_HUMAN | glycine receptor alpha 3 | -10.79 | -10.17 | -10.30 | 25.09% | CHEMBL4070615 |
| Sitagliptin | GLRA3_HUMAN | glycine receptor alpha 3 | -9.74 | N/A | N/A | 25.09% | CHEMBL4070615 |
| Canagliflozin | GRM5_HUMAN | glutamate metabotropic receptor 5 | -9.30 | -8.09 | -8.81 | 25.97% | CHEMBL1682819 |
| Metformin | GRM5_HUMAN | glutamate metabotropic receptor 5 | -5.56 | -6.13 | -5.99 | 12.77% | CHEMBL204392 |
| Glimepiride | GRM5_HUMAN | glutamate metabotropic receptor 5 | -11.58 | -10.98 | -8.88 | 32.50% | CHEMBL194538 |
| Glipizide | GRM5_HUMAN | glutamate metabotropic receptor 5 | -10.57 | -10.20 | -10.06 | 51.22% | CHEMBL4107693 |
| Sitagliptin | GRM5_HUMAN | glutamate metabotropic receptor 5 | -9.87 | -8.38 | -9.31 | 37.00% | CHEMBL3921985 |
| Canagliflozin | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -9.47 | -9.67 | -8.35 | 26.24% | CHEMBL3931600 |
| Metformin | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -5.07 | -4.94 | -5.19 | 6.85% | CHEMBL3650195 |
| Glimepiride | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -9.03 | -9.40 | -9.13 | 31.84% | CHEMBL3698263 |
| Glipizide | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -8.52 | -8.37 | -8.33 | 35.26% | CHEMBL3650213 |
| Sitagliptin | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -8.44 | -8.94 | -9.20 | 41.20% | CHEMBL3698264 |
| Canagliflozin | HRH1_HUMAN | histamine receptor H1 | -8.22 | N/A | N/A | 38.92% | CHEMBL549 |
| Metformin | HRH1_HUMAN | histamine receptor H1 | -5.57 | N/A | N/A | 9.41% | CHEMBL1096430 |
| Glimepiride | HRH1_HUMAN | histamine receptor H1 | -8.36 | N/A | N/A | 51.90% | CHEMBL2171013 |
| Glipizide | HRH1_HUMAN | histamine receptor H1 | -8.52 | N/A | N/A | 44.97% | CHEMBL2171049 |
| Sitagliptin | HRH1_HUMAN | histamine receptor H1 | -9.96 | N/A | N/A | 36.95% | CHEMBL2178580 |
| Canagliflozin | HYES_HUMAN | epoxide hydrolase 2 | -9.80 | -10.78 | -8.93 | 43.08% | CHEMBL3617997 |
| Metformin | HYES_HUMAN | epoxide hydrolase 2 | -5.88 | -5.57 | -5.02 | 12.50% | CHEMBL1458 |
| Glimepiride | HYES_HUMAN | epoxide hydrolase 2 | -10.99 | -10.52 | -9.69 | 54.74% | CHEMBL3322802 |
| Glipizide | HYES_HUMAN | epoxide hydrolase 2 | -10.51 | -9.85 | -9.40 | 47.95% | CHEMBL2436577 |
| Sitagliptin | HYES_HUMAN | epoxide hydrolase 2 | -9.70 | -10.29 | -9.19 | 36.36% | CHEMBL564975 |
| Canagliflozin | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -9.90 | N/A | N/A | 34.60% | CHEMBL200106 |
| Metformin | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -4.78 | N/A | N/A | 7.02% | CHEMBL474802 |
| Glimepiride | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -10.11 | N/A | N/A | 33.73% | CHEMBL230055 |
| Glipizide | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -8.91 | N/A | N/A | 36.63% | CHEMBL230055 |
| Sitagliptin | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -8.74 | N/A | N/A | 30.24% | CHEMBL3823257 |
| Canagliflozin | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -9.66 | -9.76 | N/A | 38.92% | CHEMBL2074679 |
| Metformin | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -4.52 | -5.08 | N/A | 10.81% | CHEMBL134 |
| Glimepiride | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -10.02 | -10.22 | N/A | 58.86% | CHEMBL472 |
| Glipizide | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -8.83 | -9.02 | N/A | 56.21% | CHEMBL472 |
| Sitagliptin | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -9.55 | -9.23 | N/A | 37.85% | CHEMBL114 |
| Canagliflozin | MIF_HUMAN | macrophage migration inhibitory factor | -7.95 | -8.54 | -8.01 | 31.25% | CHEMBL497598 |
| Metformin | MIF_HUMAN | macrophage migration inhibitory factor | -5.07 | -4.97 | -4.75 | 9.76% | CHEMBL1253381 |
| Glimepiride | MIF_HUMAN | macrophage migration inhibitory factor | -7.91 | -8.37 | -8.37 | 27.41% | CHEMBL3409229 |
| Glipizide | MIF_HUMAN | macrophage migration inhibitory factor | -7.54 | -8.84 | -8.42 | 28.64% | CHEMBL554271 |
| Sitagliptin | MIF_HUMAN | macrophage migration inhibitory factor | -7.34 | -8.24 | -6.15 | 33.02% | CHEMBL554271 |
| Canagliflozin | MK01_HUMAN | mitogen-activated protein kinase 1 | -8.87 | -8.86 | -8.94 | 31.43% | CHEMBL3654874 |
| Metformin | MK01_HUMAN | mitogen-activated protein kinase 1 | -5.03 | -4.92 | -5.03 | 5.88% | CHEMBL1975647 |
| Glimepiride | MK01_HUMAN | mitogen-activated protein kinase 1 | -9.27 | -9.23 | -10.05 | 33.99% | CHEMBL1964937 |
| Glipizide | MK01_HUMAN | mitogen-activated protein kinase 1 | -8.56 | -8.77 | -9.15 | 41.74% | CHEMBL4111027 |
| Sitagliptin | MK01_HUMAN | mitogen-activated protein kinase 1 | -8.90 | -9.46 | -8.40 | 41.70% | CHEMBL3969711 |
| Canagliflozin | MK03_HUMAN | mitogen-activated protein kinase 3 | -9.13 | -10.09 | -8.84 | 28.35% | CHEMBL213618 |
| Metformin | MK03_HUMAN | mitogen-activated protein kinase 3 | -4.80 | -5.06 | -5.09 | 4.72% | CHEMBL1336 |
| Glimepiride | MK03_HUMAN | mitogen-activated protein kinase 3 | -10.47 | -10.16 | -10.27 | 33.75% | CHEMBL3113587 |
| Glipizide | MK03_HUMAN | mitogen-activated protein kinase 3 | -8.39 | -10.17 | -9.36 | 30.39% | CHEMBL3798163 |
| Sitagliptin | MK03_HUMAN | mitogen-activated protein kinase 3 | -9.72 | -9.96 | -8.46 | 28.42% | CHEMBL3113587 |
| Canagliflozin | MTOR_HUMAN | mechanistic target of rapamycin kinase | -10.20 | -10.51 | -10.59 | 26.77% | CHEMBL2178614 |
| Metformin | MTOR_HUMAN | mechanistic target of rapamycin kinase | -4.36 | -5.07 | -4.97 | 31.82% | CHEMBL1703 |
| Glimepiride | MTOR_HUMAN | mechanistic target of rapamycin kinase | -10.32 | -10.47 | -10.56 | 31.02% | CHEMBL4100500 |
| Glipizide | MTOR_HUMAN | mechanistic target of rapamycin kinase | -11.20 | -10.41 | -10.28 | 41.90% | CHEMBL2152252 |
| Sitagliptin | MTOR_HUMAN | mechanistic target of rapamycin kinase | -10.35 | -10.25 | -10.48 | 42.45% | CHEMBL3645823 |
| Canagliflozin | NEP_HUMAN | membrane metalloendopeptidase | -9.15 | -9.29 | -9.53 | 31.48% | CHEMBL4073385 |
| Metformin | NEP_HUMAN | membrane metalloendopeptidase | -5.73 | -6.04 | -6.07 | 6.87% | CHEMBL3695450 |
| Glimepiride | NEP_HUMAN | membrane metalloendopeptidase | -9.62 | -10.23 | -11.00 | 39.74% | CHEMBL272575 |
| Glipizide | NEP_HUMAN | membrane metalloendopeptidase | -9.07 | -9.58 | -9.48 | 44.51% | CHEMBL3677664 |
| Sitagliptin | NEP_HUMAN | membrane metalloendopeptidase | -8.88 | -9.07 | -9.59 | 37.93% | CHEMBL3677664 |
| Canagliflozin | NK1R_HUMAN | tachykinin receptor 1 | -9.37 | -9.31 | -9.34 | 43.05% | CHEMBL26193 |
| Metformin | NK1R_HUMAN | tachykinin receptor 1 | -4.95 | -5.22 | -4.72 | 7.25% | CHEMBL3780820 |
| Glimepiride | NK1R_HUMAN | tachykinin receptor 1 | -10.16 | -9.28 | -9.88 | 40.72% | CHEMBL105009 |
| Glipizide | NK1R_HUMAN | tachykinin receptor 1 | -9.05 | -8.95 | -8.64 | 53.22% | CHEMBL238220 |
| Sitagliptin | NK1R_HUMAN | tachykinin receptor 1 | -9.53 | -8.90 | -9.44 | 55.30% | CHEMBL250596 |
| Canagliflozin | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -8.84 | -8.14 | -8.32 | 19.77% | CHEMBL284237 |
| Metformin | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -5.74 | -5.70 | -5.62 | 3.66% | CHEMBL284237 |
| Glimepiride | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -10.72 | -10.02 | -9.84 | 28.65% | CHEMBL2333945 |
| Glipizide | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -10.68 | -9.78 | -10.27 | 27.32% | CHEMBL2333945 |
| Sitagliptin | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -10.73 | -10.06 | -9.74 | 21.43% | CHEMBL284237 |
| Canagliflozin | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -11.70 | -10.53 | -11.25 | 25.99% | CHEMBL3357783 |
| Metformin | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -5.21 | -5.19 | -5.30 | 10.34% | CHEMBL348360 |
| Glimepiride | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -11.93 | -11.84 | -11.20 | 29.01% | CHEMBL444384 |
| Glipizide | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -10.25 | -9.73 | -9.95 | 37.10% | CHEMBL1779012 |
| Sitagliptin | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -11.17 | -10.98 | -10.22 | 33.33% | CHEMBL146764 |
| Canagliflozin | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -10.00 | -9.62 | -8.32 | 20.16% | CHEMBL435844 |
| Metformin | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -5.72 | -5.62 | -5.62 | 4.38% | CHEMBL162293 |
| Glimepiride | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -10.15 | -9.54 | -9.84 | 32.67% | CHEMBL159739 |
| Glipizide | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -9.29 | -10.09 | -10.27 | 43.37% | CHEMBL159739 |
| Sitagliptin | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -10.85 | -10.06 | -9.74 | 28.45% | CHEMBL354003 |
| Canagliflozin | NOS1_HUMAN | nitric oxide synthase 1 | -10.66 | -10.72 | -9.57 | 26.07% | CHEMBL2036268 |
| Metformin | NOS1_HUMAN | nitric oxide synthase 1 | -6.19 | -6.03 | -5.88 | 25.00% | CHEMBL269058 |
| Glimepiride | NOS1_HUMAN | nitric oxide synthase 1 | -10.29 | -10.41 | -9.78 | 28.31% | CHEMBL1270460 |
| Glipizide | NOS1_HUMAN | nitric oxide synthase 1 | -9.31 | -9.29 | -9.58 | 30.41% | CHEMBL491923 |
| Sitagliptin | NOS1_HUMAN | nitric oxide synthase 1 | -9.80 | -9.85 | -9.52 | 34.69% | CHEMBL1233715 |
| Canagliflozin | NOS2_HUMAN | nitric oxide synthase 2 | -9.09 | -10.06 | 2.82 | 25.25% | CHEMBL8105 |
| Metformin | NOS2_HUMAN | nitric oxide synthase 2 | -6.16 | -5.58 | -6.23 | 25.00% | CHEMBL269058 |
| Glimepiride | NOS2_HUMAN | nitric oxide synthase 2 | -9.46 | -10.21 | 1.20 | 31.33% | CHEMBL490886 |
| Glipizide | NOS2_HUMAN | nitric oxide synthase 2 | -8.91 | -9.53 | -6.50 | 33.66% | CHEMBL374300 |
| Sitagliptin | NOS2_HUMAN | nitric oxide synthase 2 | -9.83 | -9.67 | -8.02 | 31.20% | CHEMBL1911986 |
| Canagliflozin | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -10.87 | -10.90 | -10.72 | 28.46% | CHEMBL2002446 |
| Metformin | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -4.91 | -4.85 | -4.91 | 7.14% | CHEMBL1992371 |
| Glimepiride | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -10.10 | -10.80 | -10.72 | 33.33% | CHEMBL1996795 |
| Glipizide | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -9.40 | -9.92 | -9.92 | 41.55% | CHEMBL4113000 |
| Sitagliptin | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -9.27 | -8.97 | -9.75 | 37.60% | CHEMBL3671156 |
| Canagliflozin | OPRD_HUMAN | opioid receptor delta 1 | -8.97 | -8.23 | -8.00 | 36.64% | CHEMBL4106985 |
| Metformin | OPRD_HUMAN | opioid receptor delta 1 | -5.39 | -4.03 | -5.19 | 9.52% | CHEMBL1587149 |
| Glimepiride | OPRD_HUMAN | opioid receptor delta 1 | -8.94 | -8.90 | -8.92 | 40.72% | CHEMBL192998 |
| Glipizide | OPRD_HUMAN | opioid receptor delta 1 | -8.27 | -7.52 | -8.35 | 45.45% | CHEMBL3698816 |
| Sitagliptin | OPRD_HUMAN | opioid receptor delta 1 | -9.12 | -7.62 | -8.35 | 41.83% | CHEMBL2387329 |
| Canagliflozin | OPRK_HUMAN | opioid receptor kappa 1 | -10.60 | -10.19 | -10.30 | 36.64% | CHEMBL4106985 |
| Metformin | OPRK_HUMAN | opioid receptor kappa 1 | -4.89 | -4.87 | -5.09 | 11.11% | CHEMBL125607 |
| Glimepiride | OPRK_HUMAN | opioid receptor kappa 1 | -10.93 | -11.22 | -10.93 | 40.72% | CHEMBL192998 |
| Glipizide | OPRK_HUMAN | opioid receptor kappa 1 | -9.90 | -10.56 | -9.72 | 56.52% | CHEMBL4115104 |
| Sitagliptin | OPRK_HUMAN | opioid receptor kappa 1 | -9.95 | -9.05 | -9.51 | 45.56% | CHEMBL4112470 |
| Canagliflozin | OPRM_MOUSE | Mu-type opioid receptor | -9.82 | -8.96 | N/A | 29.69% | CHEMBL3338874 |
| Metformin | OPRM_MOUSE | Mu-type opioid receptor | -5.07 | -4.87 | N/A | 6.02% | CHEMBL2368132 |
| Glimepiride | OPRM_MOUSE | Mu-type opioid receptor | -9.16 | -9.60 | N/A | 38.01% | CHEMBL2017153 |
| Glipizide | OPRM_MOUSE | Mu-type opioid receptor | -8.90 | -8.89 | N/A | 35.32% | CHEMBL185778 |
| Sitagliptin | OPRM_MOUSE | Mu-type opioid receptor | -9.37 | -9.26 | N/A | 35.23% | CHEMBL124941 |
| Canagliflozin | OPRX_HUMAN | opioid related nociceptin receptor 1 | -8.73 | -9.18 | -8.99 | 36.05% | CHEMBL2088060 |
| Metformin | OPRX_HUMAN | opioid related nociceptin receptor 1 | -4.74 | -4.85 | -4.51 | 8.33% | CHEMBL26909 |
| Glimepiride | OPRX_HUMAN | opioid related nociceptin receptor 1 | -9.82 | -9.29 | -9.29 | 40.94% | CHEMBL3942616 |
| Glipizide | OPRX_HUMAN | opioid related nociceptin receptor 1 | -8.76 | -8.91 | -8.88 | 36.81% | CHEMBL3942616 |
| Sitagliptin | OPRX_HUMAN | opioid related nociceptin receptor 1 | -8.61 | -8.69 | -8.81 | 36.63% | CHEMBL241087 |
| Canagliflozin | P2RX3_HUMAN | purinergic receptor P2X 3 | -6.81 | -6.56 | -7.00 | 35.27% | CHEMBL3674821 |
| Metformin | P2RX3_HUMAN | purinergic receptor P2X 3 | -4.35 | -4.64 | -4.65 | 6.25% | CHEMBL3895492 |
| Glimepiride | P2RX3_HUMAN | purinergic receptor P2X 3 | -6.67 | -7.27 | -6.82 | 28.57% | CHEMBL3669757 |
| Glipizide | P2RX3_HUMAN | purinergic receptor P2X 3 | -6.77 | -6.45 | -7.09 | 34.19% | CHEMBL2011111 |
| Sitagliptin | P2RX3_HUMAN | purinergic receptor P2X 3 | -6.41 | -7.18 | -6.90 | 32.22% | CHEMBL3669710 |
| Canagliflozin | P2Y12_HUMAN | purinergic receptor P2Y12 | -9.63 | -9.58 | -10.20 | 27.05% | CHEMBL3098234 |
| Metformin | P2Y12_HUMAN | purinergic receptor P2Y12 | -4.99 | -6.24 | -5.41 | 5.30% | CHEMBL69139 |
| Glimepiride | P2Y12_HUMAN | purinergic receptor P2Y12 | -10.24 | -9.05 | -10.94 | 32.89% | CHEMBL2402146 |
| Glipizide | P2Y12_HUMAN | purinergic receptor P2Y12 | -9.29 | -8.14 | -9.52 | 39.29% | CHEMBL2402146 |
| Sitagliptin | P2Y12_HUMAN | purinergic receptor P2Y12 | -10.11 | -9.80 | -10.73 | 35.11% | CHEMBL2172144 |
| Canagliflozin | PAR1_HUMAN | coagulation factor II thrombin receptor | -9.71 | N/A | N/A | 30.39% | CHEMBL381121 |
| Metformin | PAR1_HUMAN | coagulation factor II thrombin receptor | -5.51 | N/A | N/A | 8.00% | CHEMBL4065100 |
| Glimepiride | PAR1_HUMAN | coagulation factor II thrombin receptor | -11.32 | N/A | N/A | 39.46% | CHEMBL3658409 |
| Glipizide | PAR1_HUMAN | coagulation factor II thrombin receptor | -10.76 | N/A | N/A | 38.20% | CHEMBL308052 |
| Sitagliptin | PAR1_HUMAN | coagulation factor II thrombin receptor | -9.67 | N/A | N/A | 46.39% | CHEMBL30612 |
| Canagliflozin | PDE4B_HUMAN | phosphodiesterase 4B | -10.72 | -10.04 | -10.29 | 28.87% | CHEMBL1782308 |
| Metformin | PDE4B_HUMAN | phosphodiesterase 4B | -5.53 | -5.81 | -5.85 | 6.00% | CHEMBL284970 |
| Glimepiride | PDE4B_HUMAN | phosphodiesterase 4B | -9.72 | -10.68 | -9.69 | 33.14% | CHEMBL35213 |
| Glipizide | PDE4B_HUMAN | phosphodiesterase 4B | -9.98 | -9.85 | -9.25 | 37.57% | CHEMBL286291 |
| Sitagliptin | PDE4B_HUMAN | phosphodiesterase 4B | -9.56 | -10.08 | -9.98 | 33.33% | CHEMBL505431 |
| Canagliflozin | PDE5A_HUMAN | phosphodiesterase 5A | -10.11 | -11.86 | -10.01 | 27.92% | CHEMBL298282 |
| Metformin | PDE5A_HUMAN | phosphodiesterase 5A | -5.54 | -5.91 | -5.73 | 6.92% | CHEMBL484065 |
| Glimepiride | PDE5A_HUMAN | phosphodiesterase 5A | -9.63 | -9.91 | -9.62 | 27.35% | CHEMBL509728 |
| Glipizide | PDE5A_HUMAN | phosphodiesterase 5A | -8.88 | -10.40 | -8.93 | 38.21% | CHEMBL3971214 |
| Sitagliptin | PDE5A_HUMAN | phosphodiesterase 5A | -9.17 | -9.87 | -9.70 | 32.50% | CHEMBL34744 |
| Canagliflozin | PERM_HUMAN | myeloperoxidase | -9.06 | -9.46 | -9.03 | 22.40% | CHEMBL490 |
| Metformin | PERM_HUMAN | myeloperoxidase | -5.88 | -5.90 | -6.03 | 9.33% | CHEMBL602365 |
| Glimepiride | PERM_HUMAN | myeloperoxidase | -9.11 | -9.66 | -9.41 | 26.83% | CHEMBL2347029 |
| Glipizide | PERM_HUMAN | myeloperoxidase | -8.30 | -8.29 | -8.41 | 29.59% | CHEMBL2346670 |
| Sitagliptin | PERM_HUMAN | myeloperoxidase | -9.39 | -9.66 | -8.84 | 32.22% | CHEMBL2347029 |
| Canagliflozin | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -7.93 | -8.95 | -7.88 | 37.21% | CHEMBL1096385 |
| Metformin | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -4.97 | -4.99 | -5.29 | 10.32% | CHEMBL15904 |
| Glimepiride | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -10.08 | -7.91 | -8.86 | 30.52% | CHEMBL259402 |
| Glipizide | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -8.91 | -9.26 | -9.54 | 35.47% | CHEMBL3775653 |
| Sitagliptin | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -9.98 | -9.86 | -9.64 | 30.21% | CHEMBL3775104 |
| Canagliflozin | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -2.93 | -6.17 | -8.47 | 47.30% | CHEMBL388532 |
| Metformin | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -5.08 | -4.92 | -5.14 | 6.67% | CHEMBL572806 |
| Glimepiride | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -2.87 | -5.88 | -9.25 | 53.62% | CHEMBL3233599 |
| Glipizide | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -5.88 | -7.79 | -9.23 | 36.51% | CHEMBL408897 |
| Sitagliptin | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -6.64 | -7.22 | -8.78 | 33.61% | CHEMBL3290204 |
| Canagliflozin | PPAP_HUMAN | acid phosphatase 3 | -9.43 | N/A | N/A | 13.40% | CHEMBL507996 |
| Metformin | PPAP_HUMAN | acid phosphatase 3 | -5.76 | N/A | N/A | 2.82% | CHEMBL498632 |
| Glimepiride | PPAP_HUMAN | acid phosphatase 3 | -10.22 | N/A | N/A | 19.35% | CHEMBL501717 |
| Glipizide | PPAP_HUMAN | acid phosphatase 3 | -8.41 | N/A | N/A | 20.00% | CHEMBL501717 |
| Sitagliptin | PPAP_HUMAN | acid phosphatase 3 | -8.54 | N/A | N/A | 16.24% | CHEMBL507996 |
| Canagliflozin | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -10.26 | -9.74 | -10.78 | 39.08% | CHEMBL472451 |
| Metformin | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -4.82 | -5.03 | -4.76 | 6.35% | CHEMBL2336643 |
| Glimepiride | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -9.94 | -10.91 | -9.82 | 39.18% | CHEMBL278590 |
| Glipizide | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -9.17 | -10.10 | -9.75 | 48.96% | CHEMBL3899514 |
| Sitagliptin | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -9.95 | -9.85 | -9.20 | 33.50% | CHEMBL457405 |
| Canagliflozin | PRGR_HUMAN | progesterone receptor | -2.04 | -1.46 | -7.03 | 42.73% | CHEMBL486707 |
| Metformin | PRGR_HUMAN | progesterone receptor | -5.06 | -5.05 | -5.38 | 6.42% | CHEMBL412874 |
| Glimepiride | PRGR_HUMAN | progesterone receptor | -3.87 | 0.95 | -5.73 | 39.01% | CHEMBL3094480 |
| Glipizide | PRGR_HUMAN | progesterone receptor | -4.41 | -2.62 | -7.94 | 36.50% | CHEMBL1085381 |
| Sitagliptin | PRGR_HUMAN | progesterone receptor | -9.74 | -9.82 | -9.82 | 37.11% | CHEMBL552108 |
| Canagliflozin | PTGES_HUMAN | prostaglandin E synthase | -8.22 | N/A | N/A | 30.99% | CHEMBL2387603 |
| Metformin | PTGES_HUMAN | prostaglandin E synthase | -5.70 | N/A | N/A | 10.26% | CHEMBL1683227 |
| Glimepiride | PTGES_HUMAN | prostaglandin E synthase | -9.46 | N/A | N/A | 37.95% | CHEMBL3092283 |
| Glipizide | PTGES_HUMAN | prostaglandin E synthase | -8.97 | N/A | N/A | 39.08% | CHEMBL3092283 |
| Sitagliptin | PTGES_HUMAN | prostaglandin E synthase | -8.28 | N/A | N/A | 33.82% | CHEMBL3665478 |
| Canagliflozin | SC6A4_HUMAN | solute carrier family 6 member 4 | -10.66 | -10.24 | -10.38 | 51.18% | CHEMBL2012116 |
| Metformin | SC6A4_HUMAN | solute carrier family 6 member 4 | -5.48 | -5.48 | -5.61 | 7.89% | CHEMBL220766 |
| Glimepiride | SC6A4_HUMAN | solute carrier family 6 member 4 | -11.60 | -11.25 | -11.33 | 38.01% | CHEMBL203776 |
| Glipizide | SC6A4_HUMAN | solute carrier family 6 member 4 | -10.21 | -10.08 | -10.47 | 38.89% | CHEMBL3216961 |
| Sitagliptin | SC6A4_HUMAN | solute carrier family 6 member 4 | -9.94 | -9.92 | -9.83 | 37.04% | CHEMBL404145 |
| Canagliflozin | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -9.27 | N/A | N/A | 35.90% | CHEMBL381488 |
| Metformin | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -5.38 | N/A | N/A | 8.33% | CHEMBL4077213 |
| Glimepiride | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -9.26 | N/A | N/A | 36.77% | CHEMBL426790 |
| Glipizide | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -8.76 | N/A | N/A | 44.68% | CHEMBL2147219 |
| Sitagliptin | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -8.59 | N/A | N/A | 42.36% | CHEMBL403809 |
| Canagliflozin | TLR4_HUMAN | toll like receptor 4 | -8.61 | -8.71 | -8.95 | 28.72% | CHEMBL4071705 |
| Metformin | TLR4_HUMAN | toll like receptor 4 | -5.37 | -4.80 | -5.20 | 4.17% | CHEMBL2364541 |
| Glimepiride | TLR4_HUMAN | toll like receptor 4 | -9.56 | -9.75 | -10.57 | 26.29% | CHEMBL382272 |
| Glipizide | TLR4_HUMAN | toll like receptor 4 | -8.63 | -9.04 | -9.18 | 27.14% | CHEMBL1824677 |
| Sitagliptin | TLR4_HUMAN | toll like receptor 4 | -8.65 | -8.86 | -8.88 | 27.91% | CHEMBL382272 |
| Canagliflozin | TNFA_HUMAN | tumor necrosis factor | -8.86 | N/A | N/A | 31.58% | CHEMBL3983488 |
| Metformin | TNFA_HUMAN | tumor necrosis factor | -4.89 | N/A | N/A | 5.65% | CHEMBL1595790 |
| Glimepiride | TNFA_HUMAN | tumor necrosis factor | -8.67 | N/A | N/A | 37.14% | CHEMBL1607187 |
| Glipizide | TNFA_HUMAN | tumor necrosis factor | -8.10 | N/A | N/A | 42.94% | CHEMBL1607187 |
| Sitagliptin | TNFA_HUMAN | tumor necrosis factor | -8.18 | N/A | N/A | 32.97% | CHEMBL306090 |
| Canagliflozin | TRBM_HUMAN | thrombomodulin | -9.17 | -9.56 | N/A | N/A | N/A |
| Metformin | TRBM_HUMAN | thrombomodulin | -6.14 | -5.72 | N/A | N/A | N/A |
| Glimepiride | TRBM_HUMAN | thrombomodulin | -9.62 | -7.34 | N/A | N/A | N/A |
| Glipizide | TRBM_HUMAN | thrombomodulin | -8.89 | -8.69 | N/A | N/A | N/A |
| Sitagliptin | TRBM_HUMAN | thrombomodulin | -9.65 | -8.92 | N/A | N/A | N/A |
| Canagliflozin | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -8.35 | -7.79 | N/A | N/A | N/A |
| Metformin | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -4.56 | -5.39 | N/A | N/A | N/A |
| Glimepiride | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -8.63 | -10.10 | N/A | N/A | N/A |
| Glipizide | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -8.69 | -8.01 | N/A | N/A | N/A |
| Sitagliptin | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -7.87 | -7.75 | N/A | N/A | N/A |
| Canagliflozin | TRPM8_FICAL | Uncharacterized protein | -10.98 | N/A | N/A | N/A | N/A |
| Metformin | TRPM8_FICAL | Uncharacterized protein | -5.58 | N/A | N/A | N/A | N/A |
| Glimepiride | TRPM8_FICAL | Uncharacterized protein | -10.49 | N/A | N/A | N/A | N/A |
| Glipizide | TRPM8_FICAL | Uncharacterized protein | -10.14 | N/A | N/A | N/A | N/A |
| Sitagliptin | TRPM8_FICAL | Uncharacterized protein | -9.39 | N/A | N/A | N/A | N/A |
| Canagliflozin | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -9.15 | N/A | N/A | 29.22% | CHEMBL325545 |
| Metformin | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -5.67 | N/A | N/A | 10.87% | CHEMBL504463 |
| Glimepiride | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -10.06 | N/A | N/A | 38.79% | CHEMBL500075 |
| Glipizide | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -9.17 | N/A | N/A | 39.32% | CHEMBL3684332 |
| Sitagliptin | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -8.93 | N/A | N/A | 38.89% | CHEMBL3689057 |
| Canagliflozin | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -8.72 | -8.77 | N/A | N/A | N/A |
| Metformin | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -5.64 | -5.29 | N/A | N/A | N/A |
| Glimepiride | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -9.78 | -8.94 | N/A | N/A | N/A |
| Glipizide | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -8.82 | -9.06 | N/A | N/A | N/A |
| Sitagliptin | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -8.78 | -9.36 | N/A | N/A | N/A |
| Canagliflozin | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -7.68 | -7.92 | N/A | 30.59% | CHEMBL3696397 |
| Metformin | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -4.01 | -4.65 | N/A | 4.63% | CHEMBL3696426 |
| Glimepiride | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -7.53 | -8.50 | N/A | 28.50% | CHEMBL3664218 |
| Glipizide | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -7.12 | -7.82 | N/A | 38.61% | CHEMBL3692262 |
| Sitagliptin | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -8.10 | -8.35 | N/A | 32.65% | CHEMBL3696459 |
| Canagliflozin | TRXR1_HUMAN | thioredoxin reductase 1 | -8.72 | -9.21 | -7.62 | N/A | N/A |
| Metformin | TRXR1_HUMAN | thioredoxin reductase 1 | -5.33 | -5.51 | -4.59 | N/A | N/A |
| Glimepiride | TRXR1_HUMAN | thioredoxin reductase 1 | -9.43 | -9.53 | -7.50 | N/A | N/A |
| Glipizide | TRXR1_HUMAN | thioredoxin reductase 1 | -9.08 | -9.67 | -7.23 | N/A | N/A |
| Sitagliptin | TRXR1_HUMAN | thioredoxin reductase 1 | -8.81 | -9.66 | -7.21 | N/A | N/A |
| Canagliflozin | TRY1_HUMAN | serine protease 1 | -8.26 | N/A | N/A | 38.83% | CHEMBL3642964 |
| Metformin | TRY1_HUMAN | serine protease 1 | -5.33 | N/A | N/A | 10.53% | CHEMBL149324 |
| Glimepiride | TRY1_HUMAN | serine protease 1 | -7.61 | N/A | N/A | 43.20% | CHEMBL51173 |
| Glipizide | TRY1_HUMAN | serine protease 1 | -8.15 | N/A | N/A | 45.50% | CHEMBL115707 |
| Sitagliptin | TRY1_HUMAN | serine protease 1 | -6.88 | N/A | N/A | 41.91% | CHEMBL2373440 |